168 related articles for article (PubMed ID: 22996234)
21. The value of [68Ga]Ga-DOTA-TATE PET/CT in diagnosis and management of suspected pituitary tumors.
Novruzov F; Aliyev A; Wan MYS; Syed R; Mehdi E; Aliyeva I; Giammarile F; Bomanji JB; Kayani I
Eur J Hybrid Imaging; 2021 May; 5(1):10. PubMed ID: 34181114
[TBL] [Abstract][Full Text] [Related]
22. Quantitative analysis of
Ma G; Du J; Zhang X; Liu J; Xu X; Xu B; Guan Z
Quant Imaging Med Surg; 2022 Apr; 12(4):2427-2440. PubMed ID: 35371938
[TBL] [Abstract][Full Text] [Related]
23. Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy.
Huizing DMV; Aalbersberg EA; Versleijen MWJ; Tesselaar MET; Walraven I; Lahaye MJ; de Wit-van der Veen BJ; Stokkel MPM
Cancer Imaging; 2020 Aug; 20(1):57. PubMed ID: 32778165
[TBL] [Abstract][Full Text] [Related]
24. A Systematic Investigation into the Influence of Net Charge on the Biological Distribution of Radiometalated Peptides Using [
Raheem SJ; Salih AK; Garcia MD; Sharpe JC; Toosi BM; Price EW
Bioconjug Chem; 2023 Mar; 34(3):549-561. PubMed ID: 36800496
[TBL] [Abstract][Full Text] [Related]
25. Preliminary results of biodistribution and dosimetric analysis of [
Khawar A; Eppard E; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Ann Nucl Med; 2019 Jun; 33(6):404-413. PubMed ID: 30877560
[TBL] [Abstract][Full Text] [Related]
26. Biodistribution and radiation dose estimates for
Krebs S; Pandit-Taskar N; Reidy D; Beattie BJ; Lyashchenko SK; Lewis JS; Bodei L; Weber WA; O'Donoghue JA
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):677-685. PubMed ID: 30374529
[TBL] [Abstract][Full Text] [Related]
27. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
Wild D; Bomanji JB; Benkert P; Maecke H; Ell PJ; Reubi JC; Caplin ME
J Nucl Med; 2013 Mar; 54(3):364-72. PubMed ID: 23297077
[TBL] [Abstract][Full Text] [Related]
28. 68Ga-DOTA-TATE PET vs. 123I-MIBG in identifying malignant neural crest tumours.
Naji M; Zhao C; Welsh SJ; Meades R; Win Z; Ferrarese A; Tan T; Rubello D; Al-Nahhas A
Mol Imaging Biol; 2011 Aug; 13(4):769-75. PubMed ID: 20700766
[TBL] [Abstract][Full Text] [Related]
29. Fundamental study of radiogallium-labeled aspartic acid peptides introducing octreotate derivatives.
Ishizaki A; Mishiro K; Shiba K; Hanaoka H; Kinuya S; Odani A; Ogawa K
Ann Nucl Med; 2019 Apr; 33(4):244-251. PubMed ID: 30604401
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography.
Armbruster M; Sourbron S; Haug A; Zech CJ; Ingrisch M; Auernhammer CJ; Nikolaou K; Paprottka PM; Rist C; Reiser MF; Sommer WH
Invest Radiol; 2014 Jan; 49(1):7-14. PubMed ID: 24002080
[TBL] [Abstract][Full Text] [Related]
31. Comparative evaluation of
Xia Y; Zeng C; Zhao Y; Zhang X; Li Z; Chen Y
EJNMMI Res; 2020 Apr; 10(1):36. PubMed ID: 32297029
[TBL] [Abstract][Full Text] [Related]
32.
Thakur S; Daley B; Millo C; Cochran C; Jacobson O; Lu H; Wang Z; Kiesewetter D; Chen X; Vasko V; Klubo-Gwiezdzinska J
Clin Cancer Res; 2021 Mar; 27(5):1399-1409. PubMed ID: 33355247
[TBL] [Abstract][Full Text] [Related]
33. Response to Single Low-dose
Wang H; Cheng Y; Zhang J; Zang J; Li H; Liu Q; Wang J; Jacobson O; Li F; Zhu Z; Chen X
Theranostics; 2018; 8(12):3308-3316. PubMed ID: 29930731
[No Abstract] [Full Text] [Related]
34. Physiological and tumoral uptake of (68)Ga-DOTATATE: standardized uptake values and challenges in interpretation.
Kuyumcu S; Özkan ZG; Sanli Y; Yilmaz E; Mudun A; Adalet I; Unal S
Ann Nucl Med; 2013 Jul; 27(6):538-45. PubMed ID: 23543506
[TBL] [Abstract][Full Text] [Related]
35. Preliminary experience with (68)Ga-DOTA-lanreotide positron emission tomography.
Traub-Weidinger T; Von Guggenberg E; Dobrozemsky G; Kendler D; Eisterer W; Bale R; Putzer D; Gabriel M; Virgolini I
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):52-60. PubMed ID: 20168286
[TBL] [Abstract][Full Text] [Related]
36. [Value of
Zhang S; Wang L; Wang T; Xing HQ; Huo L; Li F
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Dec; 40(6):757-764. PubMed ID: 30606385
[TBL] [Abstract][Full Text] [Related]
37. Al[
Haeger A; Soza-Ried C; Kramer V; Hurtado de Mendoza A; Eppard E; Emmanuel N; Wettlin J; Amaral H; Fernández R
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672388
[TBL] [Abstract][Full Text] [Related]
38. PET-CT imaging of pulmonary inflammation using [
Puuvuori E; Liggieri F; Velikyan I; Chiodaroli E; Sigfridsson J; Romelin H; Ingvast S; Korsgren O; Hulsart-Billström G; Perchiazzi G; Eriksson O
EJNMMI Res; 2022 Apr; 12(1):19. PubMed ID: 35394238
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of [99mTc/EDDA/HYNIC0]octreotide derivatives compared with [111In-DOTA0,Tyr3, Thr8]octreotide and [111In-DTPA0]octreotide: does tumor or pancreas uptake correlate with the rate of internalization?
Storch D; Béhé M; Walter MA; Chen J; Powell P; Mikolajczak R; Mäcke HR
J Nucl Med; 2005 Sep; 46(9):1561-9. PubMed ID: 16157541
[TBL] [Abstract][Full Text] [Related]
40. 68Ga DOTA-TATE PET/CT allows tumor localization in patients with tumor-induced osteomalacia but negative 111In-octreotide SPECT/CT.
Breer S; Brunkhorst T; Beil FT; Peldschus K; Heiland M; Klutmann S; Barvencik F; Zustin J; Gratz KF; Amling M
Bone; 2014 Jul; 64():222-7. PubMed ID: 24769333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]